^
    Back
    Association details:
    Biomarker:ATM deletion
    Cancer:Bladder Cancer
    Drug Class:PARP inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Sci Adv
    Title:

    ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer

    Published date:
    11/22/2023
    Excerpt:
    ...we observed a significant increase in PARP inhibitor sensitivity in all ATM-deleted cell lines compared to WT ATM parental lines...
    DOI:
    10.1126/sciadv.adg2263